Abstract
Administration of long-term, oral prostaglandin E2 in 2 babies with pulmonary atresia did not appear to influence pulmonary arterial smooth muscle development, nor was there evidence of damage to the vessel walls, as was previously reported after treatment of the same condition with prostaglandin E1.